The Avicenna Alliance is dedicated to ensuring the full innovation cycle of predictive medicine is represented.
The Virtual Physiological Human (VPH) Initiative, carries a non-diminishable 50% board representation on the Avicenna Alliance with Industry representatives from Medical Devices, Pharmaceuticals and Software also maintaining a 50% board membership.
The VPH Institute is a massive network of Research Organisations and Universities engaged in predictive or in silico medicine.
The VPH institute has its origins in a European Commission endorsed research area on computer modeling and simulation and has been active for over 10 years.
This partnership of industry and academia allows the Avicenna Alliance to address challenges to the predictive or in silico market from pre-clinical research all the way to post-market.
NEWS
News
Avicenna at FDA / MDIC Event in Washington, April 16 - 17
Many representatives of the Avicenna Alliance networked with good friends and in silico thought leaders from around the world at the FDA / MDIC symposium on Computation Modeling & Simulation in Washington.
The European Parliament voted the reform of General Pharmaceutical Legislation (GPL)
On April 10, the European Parliament overwhelmingly backed the reform of General Pharmaceutical Legislation (GPL), marking a pivotal moment in healthcare regulation. With a resounding majority, both the Directive and Regulation were embraced, reflecting a collaborative effort within the ENVI committee.
The Avicenna Alliance warmly welcomes Tox By Design into its esteemed ranks!
Tox by Design is a prominent European toxicological expertise firm specializing in conducting toxicological Risk Assessments (RAs) for various industries such as biotech, pharmaceuticals, cosmetics, medical devices, and API synthesis.
